Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2MTMa0P
via IFTTT